Controlled-release pharmaceutical formulations
    1.
    发明申请
    Controlled-release pharmaceutical formulations 审中-公开
    控制释放药物制剂

    公开(公告)号:US20040076668A1

    公开(公告)日:2004-04-22

    申请号:US10608817

    申请日:2003-06-25

    申请人: Pfizer Inc.

    IPC分类号: A61K031/4433 A61K009/22

    CPC分类号: A61K31/4433 A61K9/0004

    摘要: The invention provides controlled release pharmaceutical formulations having a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying essentially separate regions within the core. The drug-containing composition comprises a PDE4D inhibitor, or a pharmaceutically acceptable salt thereof, preferably (R)-2-null4-(nullnull2-(benzonull1,3nulldioxol-5-yloxy)-pyridine-3-carbonylnull-aminonull-methyl)-3-fluoro-phenoxynull-propionic acid, or a pharmaceutically acceptable salt thereof, or 2-(4-fluorophenoxy)-N-null4-(1-hydroxy-1-methyl-ethyl)-benzylnull-nicotinamide, or a pharmaceutically acceptable salt thereof, and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble, and has at least one delivery port therethrough. The invention further provides methods of reducing the nausea and emetic effects of PDE4D inhibitors, and controlled-release formulations having improved PDE4D inhibitor in vivo and in vitro profiles.

    摘要翻译: 本发明提供了具有包衣核心的控释药物制剂,其核心包含含药物的组合物和水溶胀性组合物,其各自占据核心内基本上分开的区域。 含有药物的组合物包含PDE4D抑制剂或其药学上可接受的盐,优选(R)-2- [4 - ({[2-(苯并[1,3]二氧杂环戊烯-5-基氧基) - 吡啶-3-基] 羰基] - 氨基} - 甲基)-3-氟 - 苯氧基] - 丙酸或其药学上可接受的盐,或2-(4-氟苯氧基)-N- [4-(1-羟基-1-甲基 - 乙基) ) - 苄基] - 烟酰胺或其药学上可接受的盐,以及加药剂。 芯周围的涂层是透水的,不溶于水的,并且具有至少一个通过其的输送口。 本发明还提供减少PDE4D抑制剂的恶心和止吐作用的方法,以及具有改善的PDE4D抑制剂的体内和体外外观特征的控制释放制剂。